PASSAGE BIO, INC.
Ownership & governance
Executives 5Directors 7Avg age 57Avg tenure 4.5y
WC
William Chou
Chief Executive Officer
Age 53Since 2022-10-09Profile →
+11
Executives5
Board of directors7
SK
Sandipkumar S. Kapadia→
Director/Board Member
Age 56Since 2019-11-30
AC
Athena Countouriotis→
Director/Board Member
Age 54Since 2020-01-31
MG
Maxine Gowen→
Chairman
Age 68Since 2021-08-30
DP
Derrell Porter→
Director/Board Member
Age 55Since 2021-05-26
WC
William Chou→
Director/Board Member
Age 53Since 2022-10-09
DS
Dolan Sondhi→
Director/Board Member
Age 55Since 2023-07-26
TK
Thomas Kassberg→
Director/Board Member
Age 65Since 2024-09-09
Shareholders5
| Name | Stake | Shares |
|---|---|---|
| Lynx1 Capital Management LP | 21 % | 673,759 |
| Lynx1 Capital Management LP | 19.44 % | 623,704 |
| Vestal Point Capital LP | 9.508 % | 305,000 |
| Baselake Management LLC | 7.328 % | 235,058 |
| Renaissance Technologies LLC | 4.165 % | 133,612 |
Catalog · 2026-07-09
Registry officers12
| Name | Role | Since | Shares |
|---|---|---|---|
| Eden Fucci | Chief Tech/Sci/R&D Officer | — | - |
| Kathleen Borthwick | Director of Finance/CFO | 2023-07-27 | - |
| Maxine Gowen | Chairman | 2021-08-30 | - |
| Susan Browne | Chief Tech/Sci/R&D Officer | 2021-05-31 | - |
| William Chou | Chief Executive Officer | 2022-10-09 | - |
| Athena Countouriotis | Director/Board Member | 2020-01-31 | - |
| Derrell Porter | Director/Board Member | 2021-05-26 | - |
| Dolan Sondhi | Director/Board Member | 2023-07-26 | - |
Registry · as of 2026-07-09
Institutional (13F)
Loading Form 13F holders…
Fund membership
Loading fund baskets…
Street consensus
Consensus buyMean target 15.5Range 8–23Analysts 2
8Mean 15.523
- Buy 1
- Hold 2
Broker actions40 of 42
| Firm | Action | To | Target | Date |
|---|---|---|---|---|
| TD Cowen | Downgrade | Hold | — | 2026-04-21 |
| Chardan Capital | Downgrade | Neutral | 7 | 2026-04-21 |
| Oppenheimer | Maintained | Outperform | 15 | 2026-04-21 |
| Wedbush | Downgrade | Neutral | 8 | 2026-04-21 |
| Oppenheimer | Initiated | Outperform | 30 | 2026-03-31 |
| Canaccord Genuity | Maintained | Buy | 23 | 2026-03-04 |
| Chardan Capital | Maintained | Buy | 21 | 2025-11-12 |
| Canaccord Genuity | Maintained | Buy | 67 | 2025-08-14 |
| Guggenheim | Maintained | Buy | 10 | 2025-08-14 |
| Wedbush | Maintained | Outperform | 40 | 2025-08-13 |
| Chardan Capital | Maintained | Buy | 6 | 2025-06-24 |
| Chardan Capital | Maintained | Buy | 6 | 2025-03-04 |
Firm rows and rating mix from Yahoo Finance; mean target is Yahoo’s aggregate until OpenFilings derives consensus from broker rows.